1-aryl-3-[4-(thieno[3,2-d]pyrimidin-4-yloxy)phenyl]ureas as VEGFR-2 tyrosine kinase inhibitors: Synthesis, biological evaluation, and molecular modelling studies

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Soares, Pedro ^a,b   Costa, Raquel ^c   Froufe, Hugo J C ^d   Calhelha, Ricardo C ^a,d   Peixoto, Daniela ^a   Ferreira, Isabel C F R ^d   Abreu, Rui M V ^d   Soares, Raquel ^c   Queiroz, Maria João R P ^a  

^a UNIVERSITY OF MINHO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c University of Porto   (Portugal)

^d INSTITUTO POLITÉCNICO DE BRAGANÇA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 CYANOPHENYL) 3 [4 (7 METHYLTHIENO(3,2 D)PYRIMIDIN 4 YLOXY)PHENYL]UREA; 1 (4 CYANOPHENYL) 3 [4 (THIENO(3,2 D) PYRIMIDIN 4 YLOXY)PHENYL]UREA; 1 (4 METHOXYPHENYL) 3 [4 (7 METHYLTHIENO(3,2 D)PYRIMIDIN 4 YLOXY)PHENYL]UREA; 1 (4 METHOXYPHENYL) 3 [4 (THIENO(3,2 D)PYRIMIDIN 4 YLOXY)PHENYL]UREA; 1 PHENYL 3 [4 (7 METHYLTHIENO(3,2 D)PYRIMIDIN 4 YLOXY]PHENYL]UREA; 1 PHENYL 3 [4 [THIENO(3,2 D)PYRIMIDIN 4 YLOXY]PHENYL]UREA; 4 [7 METHYLTHIENO(3,2 D)PYRIMIDIN 4 YLOXY]ANILINE; 4 [THIENO(3,2 D)PYRIMIDIN 4 YLOXY]ANILINE; BROXURIDINE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; UREA DERIVATIVE; CARBANILAMIDE DERIVATIVE; PROTEIN BINDING; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ARTICLE; CELL ASSAY; CELL VIABILITY; DRUG SCREENING; DRUG SYNTHESIS; ENZYMATIC ASSAY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IC 50; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; GENETICS; METABOLISM; MOLECULAR DOCKING; NEOPLASMS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SYNTHESIS; DRUG ANTAGONISM; DRUG EFFECT; NEOPLASM; PROTEIN BINDING;

BINDING SITES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHENYLUREA COMPOUNDS; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PYRIMIDINES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84880883258     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/154856     Document Type: Article

References (19)

1. Patan S., Vasculogenesis and angiogenesis as mechanisms of vascular network formation, growth and remodeling. Journal of Neuro-Oncology 2000 50 1-2 1 15 2-s2.0-0034470341 10.1023/A:1006493130855 (Pubitemid 32166287)
2. Folkman J., Shing Y., Angiogenesis. The Journal of Biological Chemistry 1992 267 16 10931 10934 2-s2.0-0026639806
3. Ferrara N., Gerber H.-P., LeCouter J., The biology of VEGF and its receptors. Nature Medicine 2003 9 6 669 676 2-s2.0-0037699954 10.1038/nm0603-669 (Pubitemid 36749215)
4. Lemmon M. A., Schlessinger J., Cell signaling by receptor tyrosine kinases. Cell 2010 141 7 1117 1134 2-s2.0-77953896432 10.1016/j.cell.2010.06.011
5. Baka S., Clamp A. R., Jayson G. C., A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis. Expert Opinion on Therapeutic Targets 2006 10 6 867 876 2-s2.0-33751413349 10.1517/14728222.10.6. 867 (Pubitemid 44816749)
6. Eichholz A., Merchant S., Gaya A. M., Anti-angiogenesis therapies: their potential in cancer management. Oncology Targets Therapy 2010 3 69 82
7. Hu-Lowe D. D., Zou H. Y., Grazzini M. L., Hallin M. E., Wickman G. R., Amundson K., Chen J. H., Rewolinski D. A., Yamazaki S., Wu E. Y., McTigue M. A., Murray B. W., Kania R. S., O'Connor P., Shalinsky D. R., Bender S. L., Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clinical Cancer Research 2008 14 22 7272 7283 2-s2.0-58149337448 10.1158/1078-0432.CCR-08-0652
8. Cowey L., Sonpavde G., Hutson T. E., New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib. OncoTargets and Therapy 2010 3 147 155
9. Dai Y., Guo Y., Frey R. R., Ji Z., Curtin M. L., Ahmed A. A., Albert D. H., Arnold L., Arries S. S., Barlozzari T., Bauch J. L., Bouska J. J., Bousquet P. F., Cunha G. A., Glaser K. B., Guo J., Li J., Marcotte P. A., Marsh K. C., Moskey M. D., Pease L. J., Stewart K. D., Stoll V. S., Tapang P., Wishart N., Davidsen S. K., Michaelides M. R., Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors. Journal of Medicinal Chemistry 2005 48 19 6066 6083 2-s2.0-24944543833 10.1021/jm050458h (Pubitemid 41324615)
10. Heyman H. R., Frey R. R., Bousquet P. F., Cunha G. A., Moskey M. D., Ahmed A. A., Soni N. B., Marcotte P. A., Pease L. J., Glaser K. B., Yates M., Bouska J. J., Albert D. H., Black-Schaefer C. L., Dandliker P. J., Stewart K. D., Rafferty P., Davidsen S. K., Michaelides M. R., Curtin M. L., Thienopyridine urea inhibitors of KDR kinase. Bioorganic and Medicinal Chemistry Letters 2007 17 5 1246 1249 2-s2.0-33846902851 10.1016/j.bmcl.2006.12.015 (Pubitemid 46240857)
11. Claridge S., Raeppel F., Granger M.-C., Bernstein N., Saavedra O., Zhan L., Llewellyn D., Wahhab A., Deziel R., Rahil J., Beaulieu N., Nguyen H., Dupont I., Barsalou A., Beaulieu C., Chute I., Gravel S., Robert M.-F., Lefebvre S., Dubay M., Pascal R., Gillespie J., Jin Z., Wang J., Besterman J. M., MacLeod A. R., Vaisburg A., Discovery of a novel and potent series of thieno[3,2-b] pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. Bioorganic and Medicinal Chemistry Letters 2008 18 9 2793 2798 2-s2.0-42949119327 10.1016/j.bmcl.2008.04.009 (Pubitemid 351608892)
12. Raeppel S., Claridge S., Saavedra O., Gaudette F., Zhan L., Mannion M., Zhou N., Raeppel F., Granger M.-C., Isakovic L., Déziel R., Nguyen H., Beaulieu N., Beaulieu C., Dupont I., Robert M.-F., Lefebvre S., Dubay M., Rahil J., Wang J., Ste-Croix H., Robert Macleod A., Besterman J., Vaisburg A., N-(3-fluoro-4-(2-arylthieno[3,2- b ]pyridin-7-yloxy)phenyl)-2-oxo-3- phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors. Bioorganic and Medicinal Chemistry Letters 2009 19 5 1323 1328 2-s2.0-60449116082 10.1016/j.bmcl.2009.01.068
13. Saavedra O., Claridge S., Zhan L., Raeppel F., Granger M.-C., Raeppel S., Mannion M., Gaudette F., Zhou N., Isakovic L., Bernstein N., Déziel R., Nguyen H., Beaulieu N., Beaulieu C., Dupont I., Wang J., Macleod A. R., Besterman J. M., Vaisburg A., N3-Arylmalonamides: a new series of thieno[3,2- b ]pyridine based inhibitors of c-Met and VEGFR2 tyrosine kinases. Bioorganic and Medicinal Chemistry Letters 2009 19 24 6836 6839 2-s2.0-71849092561 10.1016/j.bmcl.2009.10.095
14. 50 calculated by Invitrogen with the same FRET-based VEGFR-2 enzymatic kit used in this study. http://tools.invitrogen.com
15. Costa R., Carneiro Â., Rocha A., Pirraco A., Falcão M., Vasques L., Soares R., Bevacizumab and ranibizumab on microvascular endothelial cells: a comparative study. Journal of Cellular Biochemistry 2009 108 6 1410 1417 2-s2.0-71749104459 10.1002/jcb.22378
16. Rocha A., Azevedo I., Soares R., Anti-angiogenic effects of imatinib target smooth muscle cells but not endothelial cells. Angiogenesis 2007 10 4 279 286 2-s2.0-35748951584 10.1007/s10456-007-9080-2 (Pubitemid 350045883)
17. Morris G. M., Ruth H., Lindstrom W., Sanner M. F., Belew R. K., Goodsell D. S., Olson A. J., Software news and updates AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. Journal of Computational Chemistry 2009 30 16 2785 2791 2-s2.0-70349932423 10.1002/jcc.21256
18. Abreu R. M. V., Froufe H. J. C., Queiroz M. J. R. P., Ferreira I. C. F. R., MOLA: a bootable, self-configuring system for virtual screening using AutoDock4/Vina on computer clusters. Journal of Cheminformatics 2010 2 1, article 10 2-s2.0-78649692457 10.1186/1758-2946-2-10
19. The PyMOL Molecular Graphics System, Version 1.3, Schrödinger, LLC. September 2012, http://www.pymol.org/